Safety summary (full analysis population)
| Adverse event | Rituximab (n=604) | Alternative TNF inhibitor (n=507) |
|---|---|---|
| All adverse events | 291 (48.2) | 241 (47.5) |
| Serious adverse events | 82 (13.6) | 56 (11.0) |
| Infusion reactions | 66 (10.9) | 20 (3.9) |
| Infections | 112 (18.5) | 99 (19.5) |
| Serious infections | 23 (3.8) | 9 (1.8) |
| Number of events (rate*) | 25 (4.42) | 9 (1.94) |
| 95% CI of rate | 2.86 to 6.52 | 0.89 to 2.68 |
Values are number (%).
*Per 100 patient-years.
TNF, tumour necrosis factor.